Expertise in
8
conditions

Jurgen S. Brunner

Innsbruck, AT 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
8
conditions
Innsbruck, AT 

Overview

Jurgen Brunner practices in Innsbruck, Austria. Brunner is highly rated in 8 conditions, according to our data. Their top areas of expertise are Scleroderma, Systemic Sclerosis (SSc), Juvenile Idiopathic Arthritis (JIA), and Osteomyelitis in Children.

Their clinical research consists of co-authoring 42 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

Innsbruck, Austria
Other Locations
Krems An Der Donau, Austria
Vienna, Austria

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
Enrollment Status: Recruiting
Publish Date: February 10, 2026
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.
Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.
Enrollment Status: Recruiting
Publish Date: February 10, 2026
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3

42 Total Publications

Acceptance and impact of Nirsevimab and the RSVpreF vaccine following implementation in Austria.
Acceptance and impact of Nirsevimab and the RSVpreF vaccine following implementation in Austria.
Journal: Frontiers in public health
Published: August 15, 2025

Frequently Asked Questions about Jurgen S. Brunner

Is Jurgen S. Brunner a top-rated expert for Scleroderma?

MediFind is an objective health platform that identifies experts based on real-world data. Jurgen S. Brunner is classified as an Distinguished expert for Scleroderma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Jurgen S. Brunner participate in research or clinical trials?

Yes. Jurgen S. Brunner has published 42 articles and abstracts on conditions like Scleroderma. You can view a list of Jurgen S. Brunner's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Brunner's expertise for a condition
ConditionClose
    View All 25 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile